<DOC>
	<DOCNO>NCT02214134</DOCNO>
	<brief_summary>SPECTAlung program aim screen patient thoracic tumor identify molecular characteristic disease . The thoracic tumor include lung cancer , malignant pleural mesothelioma , thymoma thymic carcinoma stage . Once molecular characteristic identify , might possibility offer patient access target clinical trial .</brief_summary>
	<brief_title>SPECTAlung : Screening Patients With Thoracic Tumors Efficient Clinical Trial Access</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Thoracic Neoplasms</mesh_term>
	<criteria>Pathologically confirm lung cancer , MPM , thymoma thymic carcinoma stage ; Mandatory availability adequate Human Biological Material ( HBM ) : FFPE tissue sample primary tumor , recurrent tumor , metastasis , obtain time primary surgery biopsy ; minimal amount request detailed HBM guideline ; inclusion sample take recurrence diagnose followup strongly encouraged optional ; Centrally perform confirmation tumor tissue adequacy term quality/ quantity central screening ; Age â‰¥ 18 year ; At least three month lifeexpectancy ; Written inform consent accord ICH/GCP national/local regulation . Any active malignancy , except pT12 prostatic cancer Gleason score &lt; 6 , non melanomatous skin cancer carcinoma situ cervix , 5 year study entry ; Active hepatitis B/C HIV ; Any secondary malignancy ; Any severe organ dysfunction comorbidities may prevent inclusion clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>Malignant pleural mesothelioma</keyword>
	<keyword>Thymic malignancy</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Screening</keyword>
</DOC>